Literature DB >> 1803619

Discordant expression of tissue factor antigen and procoagulant activity on human monocytes activated with LPS and low dose cycloheximide.

J D Walsh1, C L Geczy.   

Abstract

The mechanisms underlying the superinduction of procoagulant activity by cycloheximide (CHX) on LPS-activated human monocytes have been investigated. Tissue factor (TF) activity of intact, viable cells was quantitated with a plasma recalcification assay and assays using chromogenic substrates specific for thrombin and factor Xa (FXa). TF antigen was measured simultaneously by immunocytochemical staining and immunoblotting with an anti-TF monoclonal antibody (MAb). Peripheral blood mononuclear cells (PBMC) activated with LPS in the presence of low dose CHX expressed more TF activity (approx. 100% increase) than cells activated with LPS alone. However, TF antigen levels were decreased approximately 70% by CHX. This discordant relationship was due primarily to differences in rates of activation of factor X (FX); LPS/CHX-treated PBMC activated nearly twice as much FX as LPS-treated cells (2.19 +/- 0.37 versus 1.10 +/- 0.21 ng FXa/10(6) PBMC/min, respectively). These studies indicate that TF cofactor activity on LPS/CHX-treated monocytes was approximately 7 times greater than that present on LPS-treated cells. Increased TF functional activity may be due to CHX-induced alterations in the type and content of phospholipids (PL) in the cell membrane. Results showed that exogenous mixed PL markedly increased TF activity on LPS-activated monocytes, but not on LPS/CHX-activated cells, without increasing TF antigen levels or altering cell viability. Membrane alterations may occur on monocytes in certain pathological or iatrogenic conditions resulting in a highly active form of TF in vivo.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1803619

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  7 in total

Review 1.  Regulation of tissue factor coagulant activity on cell surfaces.

Authors:  L V M Rao; U R Pendurthi
Journal:  J Thromb Haemost       Date:  2012-11       Impact factor: 5.824

Review 2.  Tissue factor as a tumor procoagulant.

Authors:  L V Rao
Journal:  Cancer Metastasis Rev       Date:  1992-11       Impact factor: 9.264

Review 3.  Therapeutic implications of protein disulfide isomerase inhibition in thrombotic disease.

Authors:  Robert Flaumenhaft; Bruce Furie; Jeffrey I Zwicker
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-08-07       Impact factor: 8.311

4.  Modulation of the endothelial procoagulant response to lipopolysaccharide and tumour necrosis factor-alpha in-vitro: the effects of dexamethasone, pentoxifylline, iloprost and a polyclonal anti-human IL-1 alpha antibody.

Authors:  R S Heyderman; N J Klein; O A Daramola; M Levin
Journal:  Inflamm Res       Date:  1995-07       Impact factor: 4.575

5.  Glomerular tissue factor expression in crescentic glomerulonephritis. Correlations between antigen, activity, and mRNA.

Authors:  P G Tipping; J H Erlich; J Apostolopoulos; N Mackman; D Loskutoff; S R Holdsworth
Journal:  Am J Pathol       Date:  1995-12       Impact factor: 4.307

Review 6.  Tissue factor: mechanisms of decryption.

Authors:  L Vijaya Mohan Rao; Hema Kothari; Usha R Pendurthi
Journal:  Front Biosci (Elite Ed)       Date:  2012-01-01

7.  S100A12 suppresses pro-inflammatory, but not pro-thrombotic functions of serum amyloid A.

Authors:  Yuen Ming Chung; Jesse Goyette; Nicodemus Tedla; Kenneth Hsu; Carolyn L Geczy
Journal:  PLoS One       Date:  2013-04-24       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.